Apollo Hospitals Enterprise (APOLLOHOSP) Weekly Analysis
Price & Volume
The stock price closed the week at 7732.5, reflecting a modest positive change of 0.44 percent. Trading activity remained steady with a slight increase in total volume compared to the previous week. The stock continues to trade above both its 50-day and 200-day moving averages, indicating a stable price position relative to its long-term trends.
Technicals
The market shows a positive trend with price at 7732.5, trading above both the 20-week and 50-week moving averages. The 20-week moving average, which tracks the average price over the last 20 weeks, and the 50-week moving average, representing the 50-week trend, both show upward slopes. Momentum indicators like the Relative Strength Index (RSI), which measures the speed of price changes, and the Moving Average Convergence Divergence (MACD), which compares short-term and long-term momentum, indicate active market participation. Volatility, measured by Bollinger Band width, remains moderate, reflecting the current price range and stability within the established trend.
Fundamentals
Apollo Hospitals Enterprise demonstrates robust growth, with revenue reaching ₹21,794 [Mar 2025], a 14.4% YoY increase. Net profit grew by 60.96% YoY, highlighting a significant expansion in bottom-line performance. The company maintains an operating margin of 14.6% [TTM], reflecting its core operational efficiency. Additionally, the return on equity (ROE), which measures the profit generated from shareholders' capital, stands at 19.9% [Mar 2025]. With a net debt of ₹7,987 [Sep 2025], the company continues to balance its expansion efforts with its financial obligations. These figures collectively illustrate a period of strong operational scaling and improved profitability compared to previous annual cycles.
News
During the week of April 20, 2026, Apollo Hospitals Enterprise experienced notable market activity, characterized by a significant surge in open interest within the derivatives segment on April 22 and April 24. In broader institutional developments, the company was identified as one of five healthcare stocks receiving positive attention from HSBC, which highlighted the sector's potential while noting specific industry risks. Additionally, on April 22, reports confirmed that the ICICI Group acquired fresh stakes in Apollo Hospitals as part of a broader ₹5,300 crore investment across five companies during the fourth quarter of fiscal year 2026. These events collectively reflected increased institutional interest and heightened trading volume for the stock throughout the period.
Events
The National Company Law Tribunal has approved the rescheduling of meetings for secured creditors, unsecured creditors, and equity shareholders of Apollo Hospitals Enterprise Limited and its related entities to late May 2026 as part of the ongoing composite scheme of arrangement.
Apollo Hospitals Enterprise Limited has acquired an additional 775,744 equity shares of Apollo Health and Lifestyle Limited for ₹18.69 crore, resulting in the company achieving 100% ownership of the subsidiary.
Apollo Hospitals Enterprise Limited has received the National Company Law Tribunal order regarding its composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. This procedural development marks a key step in the company's ongoing corporate restructuring process.
Apollo Hospitals Enterprise Limited has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the quarter ended 31st March 2026. This confirms that all securities received for dematerialization were processed and verified within the prescribed timelines.
The National Company Law Tribunal has approved the application for Apollo Hospitals Enterprise Limited to convene meetings of shareholders and creditors to consider its proposed composite scheme of arrangement. This step is a procedural requirement for the company to proceed with the planned restructuring involving Apollo Healthco, Keimed, and Apollo Healthtech.
Apollo Hospitals Enterprise Limited has acquired an additional 775,744 equity shares of Apollo Health and Lifestyle Limited for ₹18.69 crore, resulting in the company achieving 100% ownership of the subsidiary.
Apollo Hospitals Enterprise Limited has received the National Company Law Tribunal order regarding its composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. This procedural development marks a key step in the company's ongoing corporate restructuring process.
Apollo Hospitals Enterprise Limited has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the quarter ended 31st March 2026. This confirms that all securities received for dematerialization were processed and verified within the prescribed timelines.
The National Company Law Tribunal has approved the application for Apollo Hospitals Enterprise Limited to convene meetings of shareholders and creditors to consider its proposed composite scheme of arrangement. This step is a procedural requirement for the company to proceed with the planned restructuring involving Apollo Healthco, Keimed, and Apollo Healthtech.
Weekly Snapshot
Highlights
- The stock price closed the week at 7732.5, marking its third consecutive week of gains.
- Technical indicators show the stock is trading above its 50-week moving average, which tracks the average price over the last 50 weeks.
- Apollo Hospitals achieved 100% ownership of its subsidiary, Apollo Health and Lifestyle Limited, following an acquisition of additional shares.
- Institutional interest increased as the ICICI Group acquired fresh stakes in the company during the fourth quarter of fiscal year 2026.
- The company reported a return on equity of 19.9% as of March 2025, reflecting its operational efficiency.
What This Means
Apollo Hospitals experienced a stable week with consistent price gains and increased trading volume. The stock remains in a positive trend, supported by moving averages and positive momentum indicators like the MACD (Moving Average Convergence Divergence, which compares short-term and long-term momentum). Corporate developments included the consolidation of ownership in a subsidiary and progress on a composite scheme of arrangement. Institutional activity was also notable, with new investments reported by the ICICI Group and positive attention from HSBC regarding the healthcare sector.
Latest Quarter Info
For the quarter ending December 2025, the company demonstrated solid financial momentum, characterized by double-digit year-over-year growth in both top-line revenue and net profitability. Revenue increased by approximately 17% compared to the previous year, supported by a steady quarter-over-quarter expansion. Operating efficiency remains a key focus, with an operating margin of 15% contributing to an operating profit of 965. The bottom line reflects this operational success, as net profit grew by over 36% year-over-year, outpacing revenue growth and signaling improved cost leverage. While interest and depreciation expenses remain present, the company maintains a stable tax profile. Overall, the quarterly results indicate a consistent upward trajectory in earnings per share, reflecting a balanced approach to scaling operations while maintaining profitability margins.